- Home
- OPHC vs ITRM Comparison
OPHC vs ITRM Comparison
Compare OPHC & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPHC
- ITRM
- Stock Information
- Founded
- OPHC 2000
- ITRM 2015
- Country
- OPHC United States
- ITRM Ireland
- Employees
- OPHC N/A
- ITRM N/A
- Industry
- OPHC Major Banks
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- OPHC Finance
- ITRM Health Care
- Exchange
- OPHC Nasdaq
- ITRM Nasdaq
- Market Cap
- OPHC 43.1M
- ITRM 35.6M
- IPO Year
- OPHC N/A
- ITRM 2018
- Fundamental
- Price
- OPHC $4.60
- ITRM $1.05
- Analyst Decision
- OPHC Hold
- ITRM Strong Buy
- Analyst Count
- OPHC 1
- ITRM 2
- Target Price
- OPHC $5.25
- ITRM $7.00
- AVG Volume (30 Days)
- OPHC 16.2K
- ITRM 536.8K
- Earning Date
- OPHC 05-20-2025
- ITRM 05-13-2025
- Dividend Yield
- OPHC N/A
- ITRM N/A
- EPS Growth
- OPHC 53.23
- ITRM N/A
- EPS
- OPHC 1.33
- ITRM N/A
- Revenue
- OPHC $37,091,000.00
- ITRM N/A
- Revenue This Year
- OPHC N/A
- ITRM N/A
- Revenue Next Year
- OPHC N/A
- ITRM $108.39
- P/E Ratio
- OPHC $3.39
- ITRM N/A
- Revenue Growth
- OPHC 60.44
- ITRM N/A
- 52 Week Low
- OPHC $3.53
- ITRM $0.81
- 52 Week High
- OPHC $5.90
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- OPHC 71.98
- ITRM 44.34
- Support Level
- OPHC $4.20
- ITRM $0.88
- Resistance Level
- OPHC $4.51
- ITRM $1.14
- Average True Range (ATR)
- OPHC 0.13
- ITRM 0.10
- MACD
- OPHC 0.06
- ITRM -0.01
- Stochastic Oscillator
- OPHC 100.00
- ITRM 31.48
About OPHC OptimumBank Holdings Inc.
OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides a range of community banking services to individuals and corporate customers. Its services include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal account, money market deposit accounts, debit cards, and automated teller machines.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.